Amgen Stock Price Surpasses Analyst Targets, Trading at Over 15 Percent Premium

Amgen Inc.'s stock price has been holding steady above $430 as valuation surpasses analyst targets, with a recent close of $439.33 on August 21, 2026.

The biotech company's shares are trading at a premium of more than 15 percent above the average consensus target price of $380.43.

This raises questions about whether earnings and cash flows in the next few years can justify the current valuation or if expectations have moved ahead of fundamentals.

Amgen's recent guidance for fiscal 2026 points to earnings per share between $22.30 and $23.50, giving the market a band of expected profitability against which to gauge the present price level.